← Oncology Approval Tracker

FDA DECISION ·

Temodar

temozolomide · Merck

FDA approvalIndication revisionGlioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with refractory anaplastic astrocytoma. The revised indication removed the previous requirement for progression on nitrosourea and procarbazine treatment.

LAMPGEN ANALYSIS

Why it matters

The revised label removed an older prior-treatment constraint for refractory disease.

What research teams should watch

Apply the historical label version when auditing whether earlier therapy was required.

PRIMARY RECORDS

Sources